BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Myriad Genetics has a 12-month low of $7.35 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

About Myriad Genetics Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D.

In the preceding three months, 10 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the ...

Myriad Genetics, Inc. SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today ...